Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 18;15(7):1137.
doi: 10.3390/life15071137.

Pulmonary Hypertension: Let's Take Stock!

Affiliations
Review

Pulmonary Hypertension: Let's Take Stock!

Michele Cacia et al. Life (Basel). .

Abstract

Pulmonary hypertension (PH) encompasses a group of conditions characterized by elevated pulmonary arterial pressure, with pulmonary arterial hypertension (PAH) representing a distinct and severe subset. This review provides a comprehensive overview of the current classification system, highlighting the five clinical groups of PH and the specific hemodynamic criteria defining PAH. We discuss the complex pathophysiological mechanisms underlying PAH, including vascular remodeling, endothelial dysfunction, and genetic predisposition. Advances in diagnostic approaches are explored. Current treatment strategies targeting key molecular pathways such as endothelin, nitric oxide, and prostacyclin are reviewed alongside novel and investigational therapies. Prognostic indicators and risk stratification tools are evaluated to guide clinical management. Finally, we underscore the critical role of expert centers in accurate diagnosis, multidisciplinary care, and enrollment in clinical trials, which collectively improve patient outcomes in this challenging disease spectrum.

Keywords: pulmonary hypertension; rare disease; treatments.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The figure illustrates the progression of pulmonary hypertension from a pathophysiological perspective and the conceptual basis of the diagnostic approach, with the aim of stratifying annual mortality risk and, consequently, the type of pharmacological treatment (oral, parenteral, and transplant-based).
Figure 2
Figure 2
The WHO classification of pulmonary hypertension.
Figure 3
Figure 3
The diagnostic workup of pulmonary hypertension.
Figure 4
Figure 4
Therapeutic strategy and follow-up of pulmonary arterial hypertension.

References

    1. Frost A.E., Badesch D.B., Barst R.J., Benza R.L., Elliott C.G., Farber H.W., Krichman A., Liou T.G., Raskob G.E., Wason P., et al. The changing picture of patients with pulmonary arterial hypertension in the United States: How REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011;139:128–137. doi: 10.1378/chest.10-0075. Erratum in Chest 2011, 140, 1106. - DOI - PubMed
    1. Hoeper M.M., Humbert M., Souza R., Idrees M., Kawut S.M., Sliwa-Hahnle K., Jing Z.-C., Gibbs J.S. A global view of pulmonary hypertension. Lancet Respir. Med. 2016;4:306–322. doi: 10.1016/S2213-2600(15)00543-3. - DOI - PubMed
    1. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., Yaici A., Weitzenblum E., Cordier J.-F., Chabot F., et al. Pulmonary arterial hypertension in France: Results from a national registry. Am. J. Respir. Crit. Care Med. 2006;173:1023–1030. doi: 10.1164/rccm.200510-1668OC. - DOI - PubMed
    1. D’Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., Kernis J.T., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991;115:343–349. doi: 10.7326/0003-4819-115-5-343. - DOI - PubMed
    1. Kjellstrom B.W.M., Dahlerup H., Hesselstrand R. Swedish Pulmonary Arterial Hypertension Registry Annual Report. [(accessed on 11 May 2025)]. Available online: http://www.ucr.uu.se/spahr/arsrapporter.

LinkOut - more resources